RBC Capital Maintains Outperform on Design Therapeutics, Lowers Price Target to $19
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $20 to $19.
RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $20 to $19.